ABUS vs BK · P/E 5.4, rev $6.2M vs P/E 17, rev $20.08B
Arbutus Biopharma Corp (ABUS) versus The Bank of New York Mellon Corporation (BK) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Not investment advice. Open the ABUS and BK stock pages for the full models.
Not investment advice.